Reduced fecal short‐chain fatty acids in hispanic children with ulcerative colitis

Rotondo-Trivette, Sarah; Wang, Beibei; Luan, Yihui; Fiehn, Oliver; Sun, Fengzhu; Michail, Sonia

doi:10.14814/phy2.14918

Cited by 5 publications

(4 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Butyrate suppresses proliferation, supports differentiation, and evokes oxidative stress, leading to cell cycle arrest and apoptosis [ 175 , 176 , 177 ]. The concentration of butyrate is significantly lowered in IBD patients in comparison with healthy individuals, reflecting metabolic alterations likely caused by changes in the gut microbiota composition [ 178 , 179 , 180 ]. Typical butyrate-producing bacteria are F. prausnitzii , Eubacterium rectale , C. butyricum , Butyricicoccus pullicaecorum , Bifidobacterium spp., Anaerostipes spp., Lachnospira spp., and Roseburia spp.…”

Section: Postbiotics and Ucmentioning

confidence: 99%

Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches

et al. 2022

View full text Add to dashboard Cite

Although there are number of available therapies for ulcerative colitis (UC), many patients are unresponsive to these treatments or experience secondary failure during treatment. Thus, the development of new therapies or alternative strategies with minimal side effects is inevitable. Strategies targeting dysbiosis of gut microbiota have been tested in the management of UC due to the unquestionable role of gut microbiota in the etiology of UC. Advanced molecular analyses of gut microbiomes revealed evident dysbiosis in UC patients, characterized by a reduced biodiversity of commensal microbiota. Administration of conventional probiotic strains is a commonly applied approach in the management of the disease to modify the gut microbiome, improve intestinal barrier integrity and function, and maintain a balanced immune response. However, conventional probiotics do not always provide the expected health benefits to a patient. Their benefits vary significantly, depending on the type and stage of the disease and the strain and dose of the probiotics administered. Their mechanism of action is also strain-dependent. Recently, new candidates for potential next-generation probiotics have been discovered. This could bring to light new approaches in the restoration of microbiome homeostasis and in UC treatment in a targeted manner. The aim of this paper is to provide an updated review on the current options of probiotic-based therapies, highlight the effective conventional probiotic strains, and outline the future possibilities of next-generation probiotic and postbiotic supplementation and fecal microbiota transplantation in the management of UC.

show abstract

Section: Postbiotics and Ucmentioning

confidence: 99%

Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Fecal pellets from PBS and LCWE-injected mice were analyzed at the UC Davis West Coast Metabolomics Center for SCFAs quantification following standard operating procedures, as previously published 97,98 .…”

Section: Methods Detailsmentioning

confidence: 99%

“…Coast Metabolomics Center for SCFAs quantification following standard operating procedures, as previously published 97,98 .…”

Section: Supplementary Figure Legendsmentioning

confidence: 99%

The intestinal microbiota contributes to the development of immune-mediated cardiovascular inflammation and vasculitis in mice

Jena,

Wakita,

Gomez

et al. 2024

Preprint

View full text Add to dashboard Cite

SUMMARYAlterations in the intestinal microbiota contribute to the pathogenesis of various cardiovascular disorders, but how they affect the development of Kawasaki disease (KD), an acute pediatric vasculitis, remains unclear. We report that depleting the gut microbiota reduces the development of cardiovascular inflammation in a murine model mimicking KD vasculitis. The development of cardiovascular lesions was associated with alterations in the intestinal microbiota composition and, notably, a decreased abundance ofAkkermansia muciniphilaandFaecalibacterium prausnitzii.Oral supplementation with either of these live or pasteurized individual bacteria, or with short-chain fatty acids (SCFAs) produced by them, attenuated cardiovascular inflammation. Treatment with Amuc_1100, the TLR-2 signaling outer membrane protein fromA. muciniphila, also decreased the severity of vascular inflammation. This study reveals an underappreciated gut microbiota-cardiovascular inflammation axis in KD vasculitis pathogenesis and identifies specific intestinal commensals that regulate vasculitis in mice by producing metabolites or via extracellular proteins acting on gut barrier function.IN BRIEFIt remains unclear whether changes in the intestinal microbiota composition are involved in the development of cardiovascular lesions associated with Kawasaki disease (KD), an immune-mediated vasculitis. Jenaet al.observe alterations in the intestinal microbiota composition of mice developing vasculitis, characterized by reducedA. muciniphilaandF. prausnitzii. Oral supplementation with either of these bacteria, live or pasteurized, or with bacteria-produced short-chain fatty acids (SCFAs) or Amuc_1100, the TLR-2 signaling outer membrane protein ofA. muciniphila, was sufficient to alleviate the development of cardiovascular lesions in mice by promoting intestinal barrier function.HIGHLIGHTSAbsence or depletion of the microbiota decreases the severity of vasculitis in a murine model mimicking KD vasculitis.Supplementation ofB. wadsworthiaandB. fragilispromotes murine KD vasculitis.Decreased abundances ofF. prausnitziiandA. muciniphilaare associated with the development of cardiovascular lesions in mice.Supplementation with either live or pasteurizedA. muciniphilaandF. prausnitzii,or the TLR-2 signaling Amuc_1100, reduces the severity of vasculitis by promoting gut barrier function.

show abstract

“…We quantified the SCFAs butyrate, acetic acid, propionic acid, isovaleric acid, and formic acid using the methods that Rotondo et al described in their paper [28]. We chose these specific SCFAs as these have been the ones that are studied extensively in the literature.…”

Section: Short-chain Fatty Acid Quantificationmentioning

confidence: 99%

Short-Chain Fatty Acid Levels after Fecal Microbiota Transplantation in a Pediatric Cohort with Recurrent Clostridioides difficile Infection

Jess,

Eskander,

et al. 2023

Metabolites

View full text Add to dashboard Cite

Though antibiotics are the mainstay treatment for Clostridioides difficile, a large population of individuals infected will experience recurrence. In turn, fecal microbiota transplantation (FMT) has emerged as a promising treatment for recurrent C. difficile infection (rCDI). Mechanistically, by providing a healthy, diverse flora to the infected individual, FMT “resets” the underlying gut microbiome dysbiosis associated with rCDI. A proposed mechanism through which this occurs is via microbiome metabolites such as short-chain fatty acids (SCFAs); however, this has not been previously studied in pediatric patients. Using mass spectroscopy, we quantified pre- and post-transplant levels of acetate, isovalerate, butyrate, formate, and propionate in pediatric patients diagnosed with rCDI (n = 9). We compared pre- and post-transplant levels within the rCDI cohort at 1, 3, 6, and 12 months post-transplant and correlated these levels with healthy controls (n = 19). We witnessed a significant difference in the combined SCFA levels and the individual levels of acetate, butyrate, isovalerate, and propionate in the pre-treatment rCDI cohort compared to the healthy controls. In addition, there was a significant increase in combined SCFA levels at 12 months post-transplant within the rCDI group compared to that of their pre-transplant levels, and, more specifically, acetate, propionate, and isovalerate increased from pre-transplant to 12 months post-transplant. The longitudinal aspect of this study allowed us to identify mechanisms that contribute to the durability of responses to FMT, as well as characterize the unique patterns of short-chain fatty acid level recovery in rCDI pediatric patients.

show abstract

Reduced fecal short‐chain fatty acids in hispanic children with ulcerative colitis

Cited by 5 publications

References 20 publications

Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches

Probiotic-Based Intervention in the Treatment of Ulcerative Colitis: Conventional and New Approaches

The intestinal microbiota contributes to the development of immune-mediated cardiovascular inflammation and vasculitis in mice

Short-Chain Fatty Acid Levels after Fecal Microbiota Transplantation in a Pediatric Cohort with Recurrent Clostridioides difficile Infection

Contact Info

Product

Resources

About